Amylyx Pharmaceuticals In... (AMLX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 3.8 |
Market Cap | 326.05M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -3.82 |
PE Ratio (ttm) | -1 |
Forward PE | n/a |
Analyst | Hold |
Ask | 3.85 |
Volume | 562,528 |
Avg. Volume (20D) | 1,037,260 |
Open | 3.75 |
Previous Close | 3.75 |
Day's Range | 3.74 - 3.96 |
52-Week Range | 1.57 - 19.95 |
Beta | undefined |
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. ...
Analyst Forecast
According to 7 analyst ratings, the average rating for AMLX stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 110.25% from the latest price.
Why Price Moved
News

4 weeks ago · businesswire.com
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common StockCAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,142,857 shares of its co...

1 month ago · businesswire.com
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common StockCAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common...

2 months ago · seekingalpha.com
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving AlongThe company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 O...

3 months ago · seekingalpha.com
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call TranscriptAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2024 Earnings Call Transcript November 7, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee ...